

## Food Oral Immunotherapy: Risks, Benefits, Expected Outcomes

### ✦ Bibliography ✦

Baumert JL, Taylor SL, Koppelman SJ. Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy. *J Allergy Clin Immunol Pract.* 2018;6(2):457-465.e4. doi:10.1016/j.jaip.2017.05.006

Barni S, Liccioli G, Sarti L, Giovannini M, Novembre E, Mori F. Immunoglobulin E (IgE)-Mediated Food Allergy in Children: Epidemiology, Pathogenesis, Diagnosis, Prevention, and Management. *Medicina (Kaunas).* 2020;56(3):111. Published 2020 Mar 4. doi:10.3390/medicina56030111

Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy. *J Allergy Clin Immunol.* 2018;141(1):1-9. doi:10.1016/j.jaci.2017.11.004

Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety [published correction appears in *Lancet.* 2019 May 11;393(10184):1936]. *Lancet.* 2019;393(10187):2222-2232. doi:10.1016/S0140-6736(19)30420-9

Galvin AD, Vereda A, Rodríguez del Río P, et al. Children and caregiver proxy quality of life from peanut oral immunotherapy trials. *Clin Transl Allergy.* 2022;12(12):e12213. doi:10.1002/ct2.12213

Houben GF, Baumert JL, Blom WM, et al. Full range of population Eliciting Dose values for 14 priority allergenic foods and recommendations for use in risk characterization. *Food Chem Toxicol.* 2020;146:111831. doi:10.1016/j.fct.2020.111831

Lazizi S, Labrosse R, Graham F. Transitioning peanut oral immunotherapy to clinical practice. *Front Allergy.* 2022;3:974250. Published 2022 Aug 26. doi:10.3389/falgy.2022.974250

Le Blanc V, Samaan K, Paradis L, et al. Treatment expectations in food-allergic patients referred for oral immunotherapy. *J Allergy Clin Immunol Pract.* 2021;9(5):2087-2089. doi:10.1016/j.jaip.2020.11.027

Loke P, Orsini F, Lozinsky AC, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial [published correction appears in *Lancet Child Adolesc Health.* 2022 May;6(5):e19]. *Lancet Child Adolesc Health.* 2022;6(3):171-184. doi:10.1016/S2352-4642(22)00006-2

Lodge CJ, Waidyatillake N, Peters RL, et al. Efficacy and safety of oral immunotherapy for peanut, cow's milk, and hen's egg allergy: A systematic review of randomized controlled trials. *Clin Transl Allergy.* 2023;13(7):e12268. doi:10.1002/ct2.12268

Tice JA, Guzauskas GF, Hansen RN, et al. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. *J Manag Care Spec Pharm.* 2020;26(5):620-623. doi:10.18553/jmcp.2020.26.5.620

Vickery BP, Vereda A, Nilsson C, et al. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study [published correction appears in *J Allergy Clin Immunol Pract.* 2022 Feb;10(2):647-650]. *J Allergy Clin Immunol Pract.* 2021;9(5):1879-1889.e13. doi:10.1016/j.jaip.2020.12.029

